Acceleron Pharma (NASDAQ:XLRN)

CAPS Rating: 5 out of 5

Results 1 - 1 of 1

Recs

1
Member Avatar zzlangerhans (99.76) Submitted: 2/5/2014 4:59:26 PM : Outperform Start Price: $45.09 XLRN Score: -55.37

I'm continuing to suppress my skepticism on new IPO's, hoping not to be stuck on the sideline next time there's an Intercept. Acceleron is yet another leap of faith, as I haven't yet had time to ground myself in the science behind the company's pipeline of TGF beta-related drugs. For now, the market has spotted Acceleron a billion plus valuation presumably on the potential of sotatercept to compete with the erythropoietin analogues for the renal failure anemia market. There was another competitor not too long ago called Omontys - didn't really work out too well. Hopefully sotatercept fares better.

Results 1 - 1 of 1

Featured Broker Partners


Advertisement